Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration

Source :: Plus Company Updates. October 12, 2019
Publication Year :: 2019
Abstract: DUBLIN: Allergan plc has issued the following press release: Allergan plc, (NYSE: AGN), a leading global pharmaceutical company with a more than 70-year heritage in ophthalmology and Molecular Partners (SIX: [...]

Subjects :: Allergan PLC -- Product development
Clinical trials -- Physiological aspects
Macular degeneration -- Physiological aspects
Ranibizumab -- Physiological aspects
Medical research -- Physiological aspects
Pharmaceutical industry -- Product development -- Physiological aspects
Ophthalmology
General interest
News, opinion and commentary

Tools